drug
as of 2026-07-01MP-214
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Tanabe Pharma Corporation
2 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
2
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
NCT01625897Phase 2, Phase 3Completed
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
NCT01626885Phase 2, Phase 3Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication